FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023375628> ?p ?o ?g. }

• W2023375628 endingPage "180" @default.
• W2023375628 startingPage "175" @default.
• W2023375628 abstract "Vandetanib (ZACTIMA) is a once-daily oral anticancer drug that selectively inhibits vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection signaling. This randomized (1:1), double-blind study evaluated vandetanib (100 mg/day) or placebo in combination with docetaxel (D; 75 mg/m(2) every 3 weeks) and prednisolone (P; 2 x 5 mg/day) in 86 patients with metastatic hormone-refractory prostate cancer (mHRPC). The primary assessment was prostate-specific antigen (PSA) response (confirmed reduction of >or=50% from baseline) and a greater number of patients showed a PSA response with placebo + DP (67%) versus vandetanib + DP (40%); hazard ratio = 2.23 (one-sided 80% confidence limit = 2.90; one-sided p = 0.99). More patients experienced progression events (disease progression or death from any cause) with vandetanib + DP (65%) versus placebo + DP (60%); hazard ratio = 1.13 (one-sided 80% confidence limit = 1.44; one-sided p = 0.67). The overall incidence of adverse events was similar in both groups, although more patients experienced adverse events, leading to permanent discontinuation with vandetanib + DP (28%) versus placebo + DP (12%). However, the safety and tolerability profile for vandetanib was similar to that previously reported; adverse events that occurred more frequently in the vandetanib + DP arm were hypertension (14% vs. 2%), erythematous rash (14% vs. 2%), and exfoliative rash (12% vs. 2%). In this study of patients with mHRPC, vandetanib + DP did not demonstrate any efficacy benefit, compared with placebo + DP." @default.
• W2023375628 created "2016-06-24" @default.
• W2023375628 creator A5010872796 @default.
• W2023375628 creator A5021416004 @default.
• W2023375628 creator A5026541010 @default.
• W2023375628 creator A5035950407 @default.
• W2023375628 creator A5040678799 @default.
• W2023375628 creator A5041676778 @default.
• W2023375628 creator A5045667939 @default.
• W2023375628 creator A5085716681 @default.
• W2023375628 date "2009-04-01" @default.
• W2023375628 modified "2023-10-16" @default.
• W2023375628 title "A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer" @default.
• W2023375628 cites W1980637728 @default.
• W2023375628 cites W1994327821 @default.
• W2023375628 cites W2002384741 @default.
• W2023375628 cites W2032765836 @default.
• W2023375628 cites W2077632702 @default.
• W2023375628 cites W2080439368 @default.
• W2023375628 cites W2084863129 @default.
• W2023375628 cites W2090699402 @default.
• W2023375628 cites W2100304447 @default.
• W2023375628 cites W2103429101 @default.
• W2023375628 cites W2111060860 @default.
• W2023375628 cites W2113092779 @default.
• W2023375628 cites W2120292596 @default.
• W2023375628 cites W2125942853 @default.
• W2023375628 cites W2126565162 @default.
• W2023375628 cites W2126970264 @default.
• W2023375628 cites W2127809030 @default.
• W2023375628 cites W2137758263 @default.
• W2023375628 cites W2143289308 @default.
• W2023375628 cites W2145608595 @default.
• W2023375628 cites W2147289344 @default.
• W2023375628 cites W2149721689 @default.
• W2023375628 cites W2167331614 @default.
• W2023375628 cites W4235781850 @default.
• W2023375628 doi "https://doi.org/10.1089/cbr.2008.0588" @default.
• W2023375628 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19409038" @default.
• W2023375628 hasPublicationYear "2009" @default.
• W2023375628 type Work @default.
• W2023375628 sameAs 2023375628 @default.
• W2023375628 citedByCount "40" @default.
• W2023375628 countsByYear W20233756282012 @default.
• W2023375628 countsByYear W20233756282013 @default.
• W2023375628 countsByYear W20233756282014 @default.
• W2023375628 countsByYear W20233756282015 @default.
• W2023375628 countsByYear W20233756282016 @default.
• W2023375628 countsByYear W20233756282017 @default.
• W2023375628 countsByYear W20233756282018 @default.
• W2023375628 countsByYear W20233756282020 @default.
• W2023375628 countsByYear W20233756282021 @default.
• W2023375628 countsByYear W20233756282022 @default.
• W2023375628 crossrefType "journal-article" @default.
• W2023375628 hasAuthorship W2023375628A5010872796 @default.
• W2023375628 hasAuthorship W2023375628A5021416004 @default.
• W2023375628 hasAuthorship W2023375628A5026541010 @default.
• W2023375628 hasAuthorship W2023375628A5035950407 @default.
• W2023375628 hasAuthorship W2023375628A5040678799 @default.
• W2023375628 hasAuthorship W2023375628A5041676778 @default.
• W2023375628 hasAuthorship W2023375628A5045667939 @default.
• W2023375628 hasAuthorship W2023375628A5085716681 @default.
• W2023375628 hasConcept C121608353 @default.
• W2023375628 hasConcept C126322002 @default.
• W2023375628 hasConcept C126894567 @default.
• W2023375628 hasConcept C142724271 @default.
• W2023375628 hasConcept C143998085 @default.
• W2023375628 hasConcept C170493617 @default.
• W2023375628 hasConcept C197934379 @default.
• W2023375628 hasConcept C204787440 @default.
• W2023375628 hasConcept C27081682 @default.
• W2023375628 hasConcept C2778168870 @default.
• W2023375628 hasConcept C2778375690 @default.
• W2023375628 hasConcept C2778570526 @default.
• W2023375628 hasConcept C2780192828 @default.
• W2023375628 hasConcept C2780333294 @default.
• W2023375628 hasConcept C2781190966 @default.
• W2023375628 hasConcept C42362537 @default.
• W2023375628 hasConcept C71924100 @default.
• W2023375628 hasConcept C90924648 @default.
• W2023375628 hasConceptScore W2023375628C121608353 @default.
• W2023375628 hasConceptScore W2023375628C126322002 @default.
• W2023375628 hasConceptScore W2023375628C126894567 @default.
• W2023375628 hasConceptScore W2023375628C142724271 @default.
• W2023375628 hasConceptScore W2023375628C143998085 @default.
• W2023375628 hasConceptScore W2023375628C170493617 @default.
• W2023375628 hasConceptScore W2023375628C197934379 @default.
• W2023375628 hasConceptScore W2023375628C204787440 @default.
• W2023375628 hasConceptScore W2023375628C27081682 @default.
• W2023375628 hasConceptScore W2023375628C2778168870 @default.
• W2023375628 hasConceptScore W2023375628C2778375690 @default.
• W2023375628 hasConceptScore W2023375628C2778570526 @default.
• W2023375628 hasConceptScore W2023375628C2780192828 @default.
• W2023375628 hasConceptScore W2023375628C2780333294 @default.
• W2023375628 hasConceptScore W2023375628C2781190966 @default.
• W2023375628 hasConceptScore W2023375628C42362537 @default.
• W2023375628 hasConceptScore W2023375628C71924100 @default.
• W2023375628 hasConceptScore W2023375628C90924648 @default.

• next